Percutaneous Therapies for Hepatocellular Carcinoma: Evolution of Liver Directed Therapies

  • Huber T
  • Bochnakova T
  • Koethe Y
  • et al.
N/ACitations
Citations of this article
18Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Percutaneous ablation is a mainstay of treatment for early stage, unresectable hepatocellular carcinoma (HCC). Recent advances in technology have created multiple ablative modalities for treatment of this common malignancy. The purpose of this review is to familiarize readers with the technical and clinical aspects of both existing and emerging percutaneous treatment options for HCC.

Cite

CITATION STYLE

APA

Huber, T. C., Bochnakova, T., Koethe, Y., Park, B., & Farsad, K. (2021). Percutaneous Therapies for Hepatocellular Carcinoma: Evolution of Liver Directed Therapies. Journal of Hepatocellular Carcinoma, Volume 8, 1181–1193. https://doi.org/10.2147/jhc.s268300

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free